Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/130926
| dc.contributor.author | Gambato, Martina |
|---|---|
| dc.contributor.author | Caro Pérez, Noelia |
| dc.contributor.author | González, Patricia |
| dc.contributor.author | Cañete, Núria |
| dc.contributor.author | Mariño, Zoe |
| dc.contributor.author | Lens Garcia, Sabela |
| dc.contributor.author | Bonacci, Martín |
| dc.contributor.author | Bartrés, Concepció |
| dc.contributor.author | Sánchez Tapias, José M. (José María) |
| dc.contributor.author | Carrión, José A. |
| dc.contributor.author | Forns, Xavier |
| dc.contributor.author | Juan, Manel |
| dc.contributor.author | Pérez del Pulgar Gallart, Sofía |
| dc.contributor.author | Londoño Hurtado, María Carlota |
| dc.date | 2019-03-26T13:35:30Z |
| dc.date | 2019-03-26T13:35:30Z |
| dc.date | 2016-11-18 |
| dc.date | 2019-03-26T13:35:30Z |
| dc.identifier | 1932-6203 |
| dc.identifier | 686464 |
| dc.identifier | 27861593 |
| dc.identifier.uri | http://hdl.handle.net/2445/130926 |
| dc.description | Real-life data showed an increased incidence of bacterial infections in patients with advanced liver disease receiving a protease inhibitor (PI)-containing antiviral regimen against hepatitis C (HCV). However, the causes of this event are unknown. We hypothesized that PIs might impair innate immune responses through the inhibition of proteases participating in the anti-bacterial functions of neutrophils and monocytes. The aims of the study were to assess phagocytic and oxidative burst capacity in neutrophils and monocytes obtained from patients receiving a PI containing-antiviral regimen, and to determine cytokine secretion after neutrophil stimulation with flagellin. Forty patients with chronic HCV (80% with cirrhosis) were enrolled in the study, 28 received triple therapy (Group A) with pegylated-interferon and ribavirin for 4 weeks followed by the addition of a PI (telaprevir, boceprevir or simeprevir), and 12 patients received an interferon-free regimen (Group B) with simeprevir and sofosbuvir. Phagocytosis and oxidative burst capacity were analyzed by flow cytometry at baseline, week 4, and week 8 of therapy. In neutrophils from Group A patients, oxidative burst rate and oxidative enzymatic activity per cell significantly decreased throughout the study period (p = 0.014 and p = 0.010, respectively). Pairwise comparisons showed a decrease between baseline and week 4 and 8 of therapy. No differences were observed after the introduction of the PI. The oxidative enzymatic activity per cell in monocytes significantly decrease during the study period (p = 0.042) due to a decrease from baseline to week 8 of therapy (p = 0.037) in patients from Group A. None of these findings were observed in Group B patients. Cytokine secretion did not significantly change during the study in both groups. In conclusion, our data suggest that the use interferon (rather than the PI) has a deleterious effect on neutrophil and monocyte phagocytic and oxidative burst capacity in this cohort of patients with HCV-related advanced liver fibrosis. |
| dc.format | 14 p. |
| dc.format | application/pdf |
| dc.language | eng |
| dc.publisher | Public Library of Science (PLoS) |
| dc.relation | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0166631 |
| dc.relation | PLoS One, 2016, vol. 11, num. 11, p. e0166631 |
| dc.relation | https://doi.org/10.1371/journal.pone.0166631 |
| dc.rights | cc-by (c) Gambato, Martina et al., 2016 |
| dc.rights | http://creativecommons.org/licenses/by/3.0/es |
| dc.rights | info:eu-repo/semantics/openAccess |
| dc.subject | Hepatitis C |
| dc.subject | Malalties cròniques |
| dc.subject | Interferó |
| dc.subject | Cirrosi hepàtica |
| dc.subject | Hepatitis C |
| dc.subject | Chronic diseases |
| dc.subject | Interferon |
| dc.subject | Hepatic cirrhosis |
| dc.title | Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon |
| dc.type | info:eu-repo/semantics/article |
| dc.type | info:eu-repo/semantics/publishedVersion |
Documentos relacionados
Otros documentos del mismo autor/a
Gambato, Martina; Caro Pérez, Noelia; González, Patricia; Cañete, Nuria; Mariño, Zoe; Lens, Sabela; Bonacci, Martín; Bartres, Concepción; Sánchez Tapias, José M. (José María); Carrión, José A.; Forns, Xavier; Juan, Manel; Pérez del Pulgar Gallart, Sofía; Londoño, María Carlota
Gambato, Martina; Caro-Pérez, Noelia; González, Patricia; Cañete Hidalgo, Nuria; Mariño, Zoe; Lens, Sabela; Bonacci, Martín; Bartres, Concepció; Sánchez-Tapias, José María; Carrión Rodríguez, José Antonio; Forns, Xavier; Juan, Manuel; Pérez-Del-Pulgar, Sofía; Londoño, María Carlota; Universitat Autònoma de Barcelona
Gambato, Martina; Caro-Pérez, Noelia; González, Patricia; Cañete Hidalgo, Nuria; Mariño, Zoe; Lens, Sabela; Bonacci, Martín; Bartres, Concepció; Sánchez-Tapias, José María; Carrión Rodríguez, José Antonio; Forns, Xavier; Juan, Manuel; Pérez-Del-Pulgar, Sofía; Londoño, María Carlota; Universitat Autònoma de Barcelona
Brito Zerón, María del Pilar; Gheitasi, Hoda; Retamozo, María Soledad; Bové Boada, Alberto; Londoño Hurtado, María Carlota; Sánchez Tapias, José M. (José María); Caballero Borrego, Miguel; Kostov, Belchin; Forns, Xavier; Kaveri, Srini V.; Ramos Casals, Manuel
Lens Garcia, Sabela; Calleja, José L.; Campillo, Ana; Carrion, José A.; Broquetas, Teresa; Perello, Chrostoe; Revilla, Juan de la; Mariño, Zoe; Londoño, María Carlota; Sanchez Tapias, José M.; Urbano Ispizua, Álvaro; Forns, Xavier